CJC 1295

Drug Profile

CJC 1295

Alternative Names: CJC-1295; DAC™:GRF; DAC™:Growth hormone Releasing Factor

Latest Information Update: 21 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ConjuChem Biotechnologies
  • Class
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lipodystrophy; Somatotropin deficiency

Most Recent Events

  • 21 Mar 2007 Discontinued - Phase-I for Somatotropin deficiency in USA (Injection)
  • 21 Mar 2007 Discontinued - Phase-II for Lipodystrophy in Canada (Injection)
  • 14 Jul 2006 Suspended - Phase-II for Lipodystrophy in Canada (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top